GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OTCPK:GNMSF) » Definitions » Earnings Yield (Joel Greenblatt) %

GNMSF (Genmab AS) Earnings Yield (Joel Greenblatt) % : 12.42% (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Genmab AS Earnings Yield (Joel Greenblatt) %?

Genmab AS's Enterprise Value for the quarter that ended in Dec. 2024 was $10,359 Mil. Genmab AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $1,333 Mil. Genmab AS's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2024 was 12.42%.

The historical rank and industry rank for Genmab AS's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

GNMSF' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.78   Med: 2.55   Max: 13.87
Current: 13.87

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Genmab AS was 13.87%. The lowest was 0.78%. And the median was 2.55%.

GNMSF's Earnings Yield (Joel Greenblatt) % is ranked better than
96.98% of 1324 companies
in the Biotechnology industry
Industry Median: -13.71 vs GNMSF: 13.87

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Genmab AS's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2024 was 15.88%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Genmab AS Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Genmab AS's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Earnings Yield (Joel Greenblatt) % Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.07 2.55 4.10 5.03 12.42

Genmab AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.03 6.67 7.89 7.66 12.42

Competitive Comparison of Genmab AS's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Genmab AS's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Genmab AS's Earnings Yield (Joel Greenblatt) % falls into.


;
;

Genmab AS Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Genmab ASs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2024 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=1303.548/10358.6552
=12.58 %

Genmab AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,333 Mil.



Genmab AS  (OTCPK:GNMSF) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Genmab AS Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Genmab AS's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OTCPK:GNMSF) » Definitions » Earnings Yield (Joel Greenblatt) %
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.